Automatiqc® Medical Writing Technology

Innovative AI, cloud-based application to aid in quick and efficient document authoring

We appreciate the innovative spirit of MMS in enabling us to meet important milestones. Excellent job!
SVP, Research & Development
Biotechnology Sponsor

Free up resource time, improve quality, and bring efficiencies to the medical and regulatory writing process

Automatiqc® is a cloud-based solution that utilizes robotic process automation (RPA), a form of artificial intelligence (AI), to apply the required document formatting and style conventions. This frees up writers to focus on the key messaging, stakeholder alignment, and other key elements  that are most critical to the medical and regulatory writing process.

Additional key benefits of Automatiqc include:

  • Removes the burden of style and formatting from the regulatory or medical writer, saving time for critical data elements
  • Built-in set of rules that can be customized to meet any internal company or external audience document style requirements
  • Compounding efficiencies with document amendments, improving the quality of documents and reduces effort for the review and QC steps in subsequent drafts or document amendments
  • Complementary: processed documents are compatible with other tools, including PleaseReview, Veeva RIM and many others
  • Easy output provided in tracked changes for greater visibility to the writer

With this innovative medical writing technology, Automatiqc users are now able to focus where they can bring the greatest value – to the science of Medical & Regulatory Writing.

Get in touch to request a demo of Automatiqc!

Suggested For You

perspectives

April 8th, 2025

Updated UK Clinical Trial Regulation: The Key Changes and Impact on Development Safety Update Report (DSUR) Requirements

news

April 3rd, 2025

Datacise by MMS Wins 2025 Data Breakthrough Award for Best Data Science Solution

perspectives

March 27th, 2025

Enhancing Drug Safety Through Digital Solutions: Innovative Technologies in FDA REMS Programs

news

March 19th, 2025

MMS REMS-focused Technology bolsters Full-Service REMS Solutions

webinar

April 30th, 2025

Advancing Clinical Development with Innovative Trial Design and Regulatory Strategies

perspectives

March 6th, 2025

Overview of FDA Guidance for Industry on Assessment of Ovarian Toxicity in Premenopausal Adults During Development for Oncologic Products

webinar

March 25th, 2025

Overcoming NDA/BLA Submission Challenges: Practical Strategies for Success

perspectives

February 13th, 2025

Helping European Drug Development Companies Succeed in the US Market

news

February 12th, 2025

MMS Acquires Exploristics and KerusCloud Simulation Platform to Expand Biostatistics and Data Science Capabilities as a Global Data-Focused CRO

perspectives

January 30th, 2025

Post-PDUFA VII Updates: FDA Meetings Public Workshop & Lessons Learned

perspectives

January 21st, 2025

REMS Modifications and Revisions: A Retrospective from the Past 12 Months

regulatory intelligence

January 17th, 2025

The FDA’s AI Guidance and its Seven Steps into the Future of Drug Development